LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer
Terminated
- Conditions
- Bladder Cancer
- Registration Number
- NCT02164942
- Lead Sponsor
- Wake Forest University Health Sciences
- Brief Summary
This is a prospective, single arm, observational study examining aurora kinases and circulating tumor cells in subjects with bladder cancer being treated with standard cisplatin-based chemotherapy.
- Detailed Description
Subjects will receive neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy per standard of care. CTC and Aurora kinase expression patterns will be analyzed in subject specimens for correlation with clinicopathologic outcome. Subjects will be on study for a total of five years following cystectomy.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation of pathologic response rate and aurora kinase expression Within 6 months of subject enrollment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Carolinas Healthcare System
🇺🇸Charlotte, North Carolina, United States